바이오의약품 콜드체인 서드파티 물류 시장 규모, 점유율과 동향 분석 리포트 : 서비스별, 온도 범위별, 지역별, 부문 예측(2025-2033년)

Biopharmaceutical Cold Chain Third Party Logistics Market Summary

The global biopharmaceutical cold chain third party logistics market size was estimated at USD 30.59 billion in 2024 and is projected to reach USD 74.46 billion by 2033, growing at a CAGR of 10.54% from 2025 to 2033. This market growth is due to the rising demand for temperature-sensitive pharmaceuticals, stringent drug storage and transportation regulatory requirements, and the global expansion of biologics and vaccine distribution.

In addition, increasing outsourcing of logistics services by pharmaceutical companies is further driving market expansion. Furthermore, increasing demand for biologics, vaccines, and temperature-sensitive drugs has significantly expanded the need for reliable cold chain logistics solutions. Biologics, including monoclonal antibodies, gene therapies, and recombinant proteins, require stringent temperature control, typically between 2°C and 8°C, with some requiring ultra-low storage at -70°C or lower-to maintain their efficacy.

Moreover, the growing trend towards personalized medicine has further boosted the need for specialized logistics solutions to ensure product integrity throughout the supply chain.

Global Biopharmaceutical Cold Chain Third Party Logistics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global biopharmaceutical cold chain third party logistics market based on service, temperature range, and region:

• Services Outlook (Revenue, USD Million, 2021 - 2033)
• Transportation
  • Air Freight
  • Sea Freight
  • Overland
• Warehousing & Storage
• Packaging Solutions
• Monitoring & Visibility Solutions
• Inventory Management
• Others
• Temperature Range Outlook (Revenue, USD Million, 2021 - 2033)
• Frozen
• Ultra-frozen/Deep-Frozen
• Cryogenic
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Information Analysis
  • 1.3.1. Market Formulation & Data Visualization
• 1.4. Data Validation & Publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
  • 3.3.2. Market Restraint Analysis
• 3.4. Technological Landscape
• 3.5. Pricing Model Analysis
• 3.6. Industry Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Biopharmaceutical Cold Chain Third Party Logistics Market: Service Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Biopharmaceutical Cold Chain Third Party Logistics Market: Service Movement Analysis
• 4.3. Biopharmaceutical Cold Chain Third Party Logistics Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
• 4.4. Transportation
  • 4.4.1. Transportation market estimates and forecasts 2021 - 2033 (USD Million)
  • 4.4.2. Air Freight
    • 4.4.2.1. Air Freight market estimates and forecasts 2021 - 2033 (USD Million)
  • 4.4.3. Sea Freight
    • 4.4.3.1. Sea Freight market estimates and forecasts 2021 - 2033 (USD Million)
  • 4.4.4. Overland
    • 4.4.4.1. Overland market estimates and forecasts 2021 - 2033 (USD Million)
• 4.5. Warehousing & Storage
  • 4.5.1. Warehousing & Storage market estimates and forecasts 2021 - 2033 (USD Million)
• 4.6. Packaging Solutions
  • 4.6.1. Packaging Solutions market estimates and forecasts 2021 - 2033 (USD Million)
• 4.7. Monitoring & Visibility Solutions
  • 4.7.1. Monitoring & Visibility Solutions market estimates and forecasts 2021 - 2033 (USD Million)
• 4.8. Inventory Management
  • 4.8.1. Inventory Management market estimates and forecasts 2021 - 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Others market estimates and forecasts 2021 - 2033 (USD Million)

Chapter 5. Biopharmaceutical Cold Chain Third Party Logistics Market: Temperature Range Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Biopharmaceutical Cold Chain Third Party Logistics Market: Temperature Range Movement Analysis
• 5.3. Biopharmaceutical Cold Chain Third Party Logistics Size & Trend Analysis, by Temperature Range, 2021 to 2033 (USD Million)
• 5.4. Frozen
  • 5.4.1. Frozen market estimates and forecasts 2021 - 2033 (USD Million)
  • 5.4.2. Ultra-frozen/Deep-Frozen
    • 5.4.2.1. Ultra-frozen/Deep-Frozen market estimates and forecasts 2021 - 2033 (USD Million)
  • 5.4.3. Cryogenic
    • 5.4.3.1. Cryogenic market estimates and forecasts 2021 - 2033 (USD Million)

Chapter 6. Regional Business Analysis

• 6.1. Regional Dashboard
• 6.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033
• 6.3. North America
  • 6.3.1. North America Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key Country Dynamics
    • 6.3.2.2. Competitive Scenario
    • 6.3.2.3. Regulatory Framework
    • 6.3.2.4. U.S. Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key Country Dynamics
    • 6.3.3.2. Competitive Scenario
    • 6.3.3.3. Regulatory Framework
    • 6.3.3.4. Canada Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key Country Dynamics
    • 6.3.4.2. Competitive Scenario
    • 6.3.4.3. Regulatory Framework
    • 6.3.4.4. Mexico Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. Europe Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key Country Dynamics
    • 6.4.2.2. Competitive Scenario
    • 6.4.2.3. Regulatory Framework
    • 6.4.2.4. Germany Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.4.3. UK
    • 6.4.3.1. Key Country Dynamics
    • 6.4.3.2. Competitive Scenario
    • 6.4.3.3. Regulatory Framework
    • 6.4.3.4. UK Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key Country Dynamics
    • 6.4.4.2. Competitive Scenario
    • 6.4.4.3. Regulatory Framework
    • 6.4.4.4. France Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key Country Dynamics
    • 6.4.5.2. Competitive Scenario
    • 6.4.5.3. Regulatory Framework
    • 6.4.5.4. Italy Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key Country Dynamics
    • 6.4.6.2. Competitive Scenario
    • 6.4.6.3. Regulatory Framework
    • 6.4.6.4. Spain Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.4.7. Denmark
    • 6.4.7.1. Key Country Dynamics
    • 6.4.7.2. Competitive Scenario
    • 6.4.7.3. Regulatory Framework
    • 6.4.7.4. Denmark Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.4.8. Sweden
    • 6.4.8.1. Key Country Dynamics
    • 6.4.8.2. Competitive Scenario
    • 6.4.8.3. Regulatory Framework
    • 6.4.8.4. Sweden Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.4.9. Norway
    • 6.4.9.1. Key Country Dynamics
    • 6.4.9.2. Competitive Scenario
    • 6.4.9.3. Regulatory Framework
    • 6.4.9.4. Norway Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Asia Pacific Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.5.2. Japan
    • 6.5.2.1. Key Country Dynamics
    • 6.5.2.2. Competitive Scenario
    • 6.5.2.3. Regulatory Framework
    • 6.5.2.4. Japan Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.5.3. China
    • 6.5.3.1. Key Country Dynamics
    • 6.5.3.2. Competitive Scenario
    • 6.5.3.3. Regulatory Framework
    • 6.5.3.4. China Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key Country Dynamics
    • 6.5.4.2. Competitive Scenario
    • 6.5.4.3. Regulatory Framework
    • 6.5.4.4. India Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key Country Dynamics
    • 6.5.5.2. Competitive Scenario
    • 6.5.5.3. Regulatory Framework
    • 6.5.5.4. South Korea Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.5.6. Australia
    • 6.5.6.1. Key Country Dynamics
    • 6.5.6.2. Competitive Scenario
    • 6.5.6.3. Regulatory Framework
    • 6.5.6.4. Australia Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.5.7. Thailand
    • 6.5.7.1. Key Country Dynamics
    • 6.5.7.2. Competitive Scenario
    • 6.5.7.3. Regulatory Framework
    • 6.5.7.4. Thailand Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Latin America Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. Brazil Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Argentina Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
• 6.7. MEA
  • 6.7.1. MEA Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. South Africa Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.7.3. Saudi Arabia
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Saudi Arabia Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. UAE Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Competitive Scenario
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. Kuwait Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.7.6. Oman
    • 6.7.6.1. Key Country Dynamics
    • 6.7.6.2. Competitive Scenario
    • 6.7.6.3. Regulatory Framework
    • 6.7.6.4. Oman Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)
  • 6.7.7. Qatar
    • 6.7.7.1. Key Country Dynamics
    • 6.7.7.2. Competitive Scenario
    • 6.7.7.3. Regulatory Framework
    • 6.7.7.4. Qatar Biopharmaceutical Cold Chain Third Party Logistics market, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company Categorization
• 7.2. Company Market Position Analysis, 2024
• 7.3. Company Profiles
  • 7.3.1. Cardinal Health
    • 7.3.1.1. Company overview
    • 7.3.1.2. Financial performance
    • 7.3.1.3. Service benchmarking
    • 7.3.1.4. Strategic initiatives
  • 7.3.2. DHL Group
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Service benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Agility
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Service benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. SF Express
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Service benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Kinesis Medical B.V.
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Service benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. United Parcel Service of America, Inc.
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Service benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Barrett Distribution
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Service benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Cencora
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Service benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. DB Schenker
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Service benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. FedEx
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Service benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. KUEHNE + NAGEL
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Service benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Kerry Logistics Network Ltd
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Service benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Freight Logistics Solutions
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Service benchmarking
    • 7.3.13.4. Strategic initiatives